+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serologic markers for cytomegalovirus in acute coronary syndromes



Serologic markers for cytomegalovirus in acute coronary syndromes



Revista Portuguesa de Cardiologia 22(5): 619-631



Several studies relate cytomegalovirus (CMV) infection to the development of atherosclerosis. Its influence in triggering acute coronary syndromes (ACS) is not known. We set out to identify a relationship between CMV infection, occurrence of ACS and prognosis. Serologic markers (IgM and IgG) for CMV were tested prospectively at admission and at 30 days, in patients (pts) admitted to our CCU for ACS. Serologic markers for CMV were also tested in a group of pts with stable coronary artery disease admitted for elective coronary angiography. A greater than two-fold elevation of IgG titer at 30 days was defined as reactivation/reinfection. At 30 days and six months, the composite endpoint of death, myocardial (re)infarction and re-admission for unstable angina was evaluated. There were 60 pts with ACS in the study group (age 63 +/- 10 years, 75% male) and 31 pts in the control group (age 64 +/- 10 years, 71% male). On admission, 95% of the pts with ACS and 81% in the control group presented a positive IgG (p = 0.029). In the study group, at 30 days, the only pt with a 3-fold titer elevation had an endpoint. The percentage was 17% for the group with a > or = 2- and < 3-fold elevation and 11% in the group without reactivation (p = 0.034). At six months, 50% of the patients with a greater than 2-fold titer elevation and 15% of the remaining patients had an endpoint (p = 0.017). In the control group, at 30 days, 3 pts (10%) had a significant elevation in IgG titer, > or = 2- and < 3-fold, without endpoint. In pts with ACS, we found a higher prevalence of serologic markers for CMV than in pts with stable coronary disease. An elevation in IgG titer for CMV was associated with a worse outcome at 30 days and six months.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050285387

Download citation: RISBibTeXText

PMID: 12940177


Related references

Inflammation markers and risk stratification in patients with acute coronary syndromes: design of the SIESTA Study (Systemic Inflammation Evaluation in Patients with non-ST segment elevation Acute coronary syndromes). Revista Espanola de Cardiologia 56(4): 389-395, 2003

Presence and severity of Chlamydia pneumoniae and Cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes. International Heart Journal 47(4): 511-519, 2006

Serologic evidence of current Chlamydia pneumoniae infection in acute coronary syndromes. Canadian Journal of Cardiology 16(Suppl. F): 161F, 2000

Use of biochemical markers in acute coronary syndromes. IFCC scientific division, committee on standardization of markers of cardiac damage. Clinical Chemistry & Laboratory Medicine 37(6): 687-693, 1999

Correlation between biochemical markers and coronary angiography in patients with non-ST elevation acute coronary syndromes. Arquivos Brasileiros de Cardiologia 86(3): 223-231, 2006

Acute coronary syndromes: from the laboratory markers to the coronary vessels. Biomarker Insights 1: 123-130, 2007

Timing of coronary angiography and outcome in patients with non-ST elevation acute coronary syndromes and kidney disease: real-world data from the acute coronary syndromes Israeli survey. Cardiology 119(4): 224-234, 2011

Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. New England Journal of Medicine 341(4): 226-232, 1999

Should primary percutaneous coronary intervention be the preferred method of myocardial reperfusion for ST elevation acute coronary syndromes in patients with renal failure? Acute coronary syndromes in Israel 2002 national survey. Circulation 108(17 Suppl.): IV-614, 2003

Cytomegalovirus in acute coronary syndromes: will the killer be identified by their footprints this time?. Revista Portuguesa de Cardiologia 22(5): 633-637, 2003

Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. Clinical Chemistry and Laboratory Medicine 37(6): 687-693, 1999

Cytomegalovirus localization in atherosclerotic plaques is associated with acute coronary syndromes: report of 105 patients. Methodist Debakey Cardiovascular Journal 8(2): 42-46, 2012

Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy. Circulation 105(8): 928-932, 2002

Very early percutaneous coronary intervention eliminates the adverse prognostic effect of elevated serum markers in non-ST-elevation acute coronary syndromes. European Heart Journal 24(Abstract Suppl.): 68, August-September, 2003

The use of cardiac markers in acute coronary syndromes. Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum 230: 50-59, 1999